Zimbabwe has rejected a significant US health deal valued at $367m (£272m) over five years over the United States' demand for confidential information.
This move was revealed after a internal memorandum dated December was leaked, which showed President Emmerson Mnangagwa deemed the deal was "skewed".
An official spokesman later explained that the US was seeking genetic material for scientific study and profit while was not willing to share the resulting advantages from future treatments.
"We will now turn to the challenging and unfortunate process of ending our support in Zimbabwe," said American envoy to Zimbabwe Pamela Tremont publicly.
The US Embassy noted the US had provided more than $1.9bn for health programmes to Zimbabwe during the past twenty years.
A physicians' group in Zimbabwe has urged further negotiations to find a deal acceptable to both sides so the nation's vital HIV programme can be sustained.
Wider Background
This rejection follows a comparable situation in neighbouring Kenya, where a high court halted a similar deal with the US after concerns were filed about the security of Kenyans' health data.
Since returning to office last year, US President Donald Trump has slashed overseas assistance and closed the key foreign aid agency.
USAID had administered assistance for the American government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government deals to boost openness and responsibility.
As per statements, 16 African countries have to date agreed to these new agreements, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to gone towards "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"It is our view this cooperation could have provided immense benefits for the people of Zimbabwe, especially the 1.2 million men, women and children currently on antiretroviral therapy via US-supported programmes," the Ambassador added.
However, government spokesperson Nick Mangwana argued the arrangement was "asymmetrical".
"Our nation was requested to provide its biological resources and data for a long time, with no equivalent promise of access to any scientific breakthroughs – like new medicines or tests – that could be developed from that provided information," his statement read.
"Effectively, our country would provide the basic resources for scientific discovery with no assurance that the resulting innovations would be accessible to our citizens if a new health crisis arise."
Sovereignty and Global Health
He also pointed out that the American exit from the global health body and its pursuit of one-on-one deals were upending systems previously set up through the international health agency.
The spokesperson cited its Pathogen Access and Benefit Sharing framework created to manage future pandemics.
"This system is intended to guarantee that when a nation provides its samples, the benefits – including medicines and cures – are distributed fairly, not commercialised solely by those with the funds to develop them."
The government's concerns over the US deal "should not be misconstrued as anti-American sentiment," Mangwana stressed.
"We welcome continued dialogue with our US partners on how subsequent co-operation could be designed in a way that respects the independence and dignity of each country."
Medical Community Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the government's concerns, but urged that talks must proceed considering much of the nation's Aids initiatives were funded by external financing.
"Where specific concerns arise, including those relating to data governance or implementation frameworks, these can frequently be resolved via detailed discussion and negotiated safeguards," it commented.
The situation highlights the continuing tensions between accepting crucial foreign assistance and protecting a country's data in an increasingly data-driven world.